Currently, three parenteral IFN-β preparations are approved for the treatment of MS: IFN-β-1b is subcutaneously injected every other day, IFN-β-1a is subcutaneously injected three times a week, and IFN-β-1a is injected intramuscularly once a week. Here, IFNB1 is linked to myeloid sarcoma.